Intensity Therapeutics (INTS) Accumulated Expenses (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Accumulated Expenses came in at $1.6 million in Q1 2026, up 55.23% YoY from $1.0 million in Q1 2025, and up 2.74% on a QoQ basis from $1.5 million in Q4 2025.
Intensity Therapeutics (INTS) Accumulated Expenses (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Accumulated Expenses data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 55.23% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 55.23% YoY) and the FY2025 annual result came in at $1.5 million, up 201.57% from the prior year.
- Accumulated Expenses climbed to $1.6 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.7 million in Q3 2024 to a low of $355006.0 in Q3 2023.
- A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 392.67% — and 2025, when it sank 67.92%.
- Tracing INTS's Accumulated Expenses over 5 years: stood at $1.7 million in 2022, then slumped by 48.32% to $891000.0 in 2023, then sank by 42.99% to $508000.0 in 2024, then soared by 201.57% to $1.5 million in 2025, then increased by 2.74% to $1.6 million in 2026.
- The last three Accumulated Expenses figures came in at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $561000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.57 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 561,000.00 |
| Jun 30, 2025 | 941,000.00 |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 508,000.00 |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 891,000.00 |
| Sep 30, 2023 | 355,006.00 |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 891,000.00 |
| Dec 31, 2022 | 1.72 Mn |